Skip to content

The utilization of sTWEAK in the assessment of the disease activity of lupus erythematosus

TWEAK/Fn14 signaling modulates keratinocytes bidirectionally and emerges as therapeutic target under inflammatory microenviroments

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RDC-17014027
Enrollment
Unknown
Registered
2017-12-18
Start date
2017-12-20
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lupus erythematosus

Interventions

Control group:methylprednisolone or other glucocorticoids
sTWEAK group:methylprednisolone or other glucocorticoids
Healthy control group:None

Sponsors

Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 75 years male or female; 2. Dignosed as lupus erythematosus; 3. who voluntarily participates in this trail and signs the informed consent.

Exclusion criteria

Exclusion criteria: (1) With overlapping connective tissue disease, mixed connective tissue disease or undifferentiated connective tissue disease; (2) Suffering from other autoimmune skin diseases and cutaneous vasculitis such as bullous pemphigoid, allergic purpura, Behcet's disease,et al; (3) With other inflammatory skin diseases, including psoriasis, eczema or atopic dermatitis,et al; (4) With other autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease (Crohn's disease and ulcerative colitis),et al; (5) Suffering from other systemic disease such as coronary atherosclerotic heart disease or diabetes; (6) Suffering from viral infectious skin diseases such as verruca vulgaris; (7) Under the period of severe local or systemic, acute or chronic infection; (8) With hepatitis B or C; or HIV antibody positivity; (9) With benign or malignant tumor; (10) Other conditions that researchers consider not appropriate to take part in this trial.

Design outcomes

Primary

MeasureTime frame
serum sTWEAK;urine;

Secondary

MeasureTime frame
autoantibodies;complements;biochemical assay;erythrocyte sedimentation rate;blood routine;urine routine;C reactive protein;

Countries

China

Contacts

Public ContactXia Yumin

Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University

xiayumin1202@163.com+86 029-87679327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026